Pipeline

Pipeline Overview

CategoryProduct CandidateIndicationDiscoveryPreclinicalPhase 1Phase 2Phase 3Market
Virology: Liver
HCV
Protease Inhibitor

Glecaprevir (part of pangenotypic, 2-DAA combo) Mavyert logo

 
HBV
Core Inhibitor

EDP-514

 
Virology: Respiratory
RSV
N-Protein Inhibitor

EDP-938 RSVPEDs

 

EDP-938 RSVTx

 

EDP-938 (initiating in 2H22)RSV-HR

 
L-Protein Inhibitor

EDP-323

 
hMPV
Non-Fusion Inhibitor

 
COVID-19
SARS-CoV-2 Inhibitor

EDP-235

 
Discovery or Preclinical
RSV, HBV, COVID-19, other

 
For Out-Licensing
NASH
FXR Agonists

EDP-305 (Phase 2), EDP-297 (Phase 1)

 
Virology: Liver
HCV Protease Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

Glecaprevir (part of pangenotypic,
2-DAA combo) Mavyert logo  

HBV Core Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-514   

Virology: Respiratory
RSV N-Protein Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-938 RSVPEDs 

RSV N-Protein Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-938 RSVTx 

RSV N-Protein Inhibitor - initiating in 2H22
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-938 RSV-HR 

RSV L-Protein Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-323   

hMPV Non-Fusion Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

   

COVID-19 SARS-CoV-2 Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-235  

Discovery or Preclinical
RSV, HBV, COVID-19, other
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

   

For Out-Licensing
NASH FXR Agonists
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-305 (Phase 2), EDP-297 (Phase 1)   

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.).